PET imaging in lymphoma: An update on clinical trails guidelines and clinical practice indications

Joint Event on 34^th Euro-Global Summit on Cancer Therapy & Radiation Oncology & 6^th International Conference on Big Data Analysis and Data Mining & 13^th International Conference on Orthopedics, Arthroplasty and Rhe

July 25-27, 2019 London, UK

Manuela Matesan

University of Washington, USA

Keynote: J Cancer Sci Ther

Abstract :

This presentation includes a case-based review illustrating the importance in clinical practice of 18F-FDG -PET images utilization for the initial staging and treatment response assessment in lymphoma patients. A discussion regarding 18F-FDG -avidity for different types of lymphomas and the side effects of the first and second line lymphoma treatments which every nuclear medicine radiologist needs to be familiar with in order to avoid pitfalls in image interpretation is provided. There is included also an overall review of changes presented in the new response evaluation criteria RECIL 2017 as compared to the standard previously published criteria. Learning Objectives include identify differences in Fluorodeoxyglucose (18F-FDG) -avidity based on the histopathologic subtype of lymphoma and becoming familiar with particularities of different types of lymphoma; Summarize the major indications to perform FDG-PET in patients with lymphoma and pearls and pitfalls in image interpretation Discuss criteria for oncologic response assessment.

Recent Publications

1. Barrington S F, Mikhaeel N G, Kostakoglu L, Meignan M, Hutchings M, Müeller S P, et al., (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of clinical oncology 32(27):3048-58.

2. Pelosi E, Penna D, Douroukas A, Bello M, Amati A, Arena V, et al., (2011) Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. The quarterly journal of nuclear medicine and molecular imaging 55(4):469-75.

3. Adams H J, Kwee T C, de Keizer B, Fijnheer R, de Klerk J M and Nievelstein R A (2014) FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. European journal of nuclear medicine and molecular imaging. 41(3):565-74.

4. El-Galaly T C, d'Amore F, Mylam K J, de Nully Brown P, Bogsted M, Bukh A, et al., (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomographystaged treatment-naive patients with Hodgkin. J Clin Oncol. 30(36):4508-14.

Biography :

Manuela Matesan involved in imaging interpretations in particular PET scans for oncologic patients. I was previously involved in several oncologic treatment projects including radioimmunotherapy using 90Yttrium labeled anti-CD20 (Ibritumomab tiuxetan) and radiolabeled anti-CD 45 antibodies in patients with hematologic malignancies. Results of these studies have been materialized in published manuscripts and conferences presentations. Also, I am currently involved in projects regarding side effects of lymphoma treatments.

E-mail: mmatesan@uw.edu